Rituximab and immune tolerance in severe hemophilia A: A consecutive national cohort

Journal of Thrombosis and Haemostasis

Volumn 7, Issue 5, 2009, Pages 787-794

  Collins, Peter W ^a   Mathias, M ^b   Hanley, J ^c   Keeling, D ^d   Keenan, R ^e   Laffan, M ^f   Perry, D ^g   Liesner, R ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c VICTORIA HOSPITAL   (United Kingdom)

^d CHURCHILL HOSPITAL   (United Kingdom)

^e ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Hemophilia A; Immune tolerance; Inhibitor; Rituximab

Indexed keywords

AZATHIOPRINE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; MYCOPHENOLIC ACID; PREDNISOLONE; RITUXIMAB;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DRUG RESPONSE; DRUG USE; ERADICATION THERAPY; FOLLOW UP; HEADACHE; HEALTH SURVEY; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; NAUSEA; PRIORITY JOURNAL; SUBSTITUTION THERAPY; UNITED KINGDOM;

ANTIBODIES, MONOCLONAL; COHORT STUDIES; GREAT BRITAIN; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE;

EID: 65349142616     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03332.x     Document Type: Article

References (31)

1. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004; 127: 379-91.
2. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
3. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: A guideline from the UK Haemophilia Centre Doctors' Organisation. Br J Haematol 2006; 133: 591-605.
4. Gringeri A, Mannucci PM. Italian Association of Haemophilia Centres Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611-9.
5. Astermark J, Donfield SM, DiMichele DM, Gringeri A, Gilbert SA, Waters J, Berntorp E, FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
6. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: A systematic review. Haemophilia 2003; 9: 464-520.
7. Scalone L, Mantovani LG, Mannucci PM, Gringeri A, The COCIS Study Investigators. Quality of life is associated to the orthopaedic status in haemophilic patients with inhibitors. Haemophilia 2006; 12: 154-62.
8. Dimichele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: Consensus recommendations 1. Haemophilia 2007; 13(Suppl. 1): 1-22.
9. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: A systematic review. Haemophilia 2003; 9: 436-63.
10. Collins PW. Novel therapies for immune tolerance in haemophilia A. Haemophilia 2006; 12(Suppl. 6): 94-101.
11. Mathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of allo-immune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-8.
12. Linde R, Escuriola Ettinghausen C, Konigs C, Dunsch D, Stoll H, Kreuz W. Rituximab as a new inhibitor elimination agent in high titer inhibitor patients - a long-term follow-up. Haemophilia 2004; 10(Suppl. 3): 60 (Abstract 51).
13. Franchini M, Mengoli C, Lippi G, Targher G, Montagnana M, Salvagno GL, Zaffanello M, Cruciana M. Immune tolerance with rituximab in congenital haemophilia with inhibitors: A systematic review based on individual patients' analysis. Haemophilia 2008; 14: 903-12.
14. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action. Am J Transplant 2006; 6: 859-66.
15. Curtin J, Misra A, Teo J, Webster B, Lammi A. Use of rituximab as an alternative strategy for the management of difficult high titre inhibitors in children with haemophilia A. Haemophilia 2004; 10(Suppl. 3): 57 (Abstract 30).
16. Carcao M, St Louis J, Poon MC, Grunebaum E, Lacroix S, Stain AM, Blanchette VS, Rivard GE. On behalf of the inhibitor subcommittee of the association of hemophilia clinic directors of Canada. Rituximab for congenital haemophiliacs with inhibitors: A Canadian experience. Haemophilia 2006; 12: 7-18.
17. Mateo J, Badell I, Forner R, Borrell M, Tixxano E, Fontcuberta J. Successful suppression using Rituximab of a factor VIII inhibitor in a boy with severe congenital haemophilia: An example of a significant decrease of treatment costs. Thromb Haemost 2006; 95: 386-7.
18. Moschovi M, Aronis S, Trimis G, Platokouki H, Salavoura K, Tzortzatou-Stathopoulou F. Rituximab in the treatment of high responding inhibitors in severe haemophilia A. Haemophilia 2006; 12: 95-9.
19. Fox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia 2006; 12: 218-22.
20. Neme D, Candela M, Perez Bianco R. Rituximab for the management of alloimmune antibodies in a patient with severe haemophilia A and a giant psuedotumor. Haemophilia 2006; 12(Suppl. 2): Abstract 408.
21. Hawkins SF, West S, Keenan R. A novel immunomodulatory regime for the eradication of inhibitors to factor VIII in a severe haemophiliac. J Thromb Haemost 2005; 3(Suppl. 1): Abstract 1435.
22. Curry N, Stanworth S, Keeling D. The use of rituximab in two children with allo-antibodies towards factor VIII. Br J Haematol 2006; 133: 214-5.
23. Cooper N, Khair K, Mathias M, Leisner R. Rituximab is effective and well tolerated in children with hemophilia and factor VIII inhibitors. Blood 2006; 108: Abstract 1031.
24. Chowdhury F, Lawrence K, Baglin T, Perry D. Rituximab failure in a patient with allo-FVIII inhibitor. Br J Haematol 2006; 135: 412.
25. Biss TT, Velangi MR, Hanley JP. Failure of rituximab to induce immune tolerance in a boy with severe haemophilia A and an alloimmune factor VIII antibody: A case report and review of the literature. Haemophilia 2006; 12: 280-4.
26. Avest PC, Gouw SC, van Helden PM, Voorberg J, van den Berg HM. Discordant Antibody Response in Monozygotic Twins with Severe Haemophilia A. J Thromb Haemost 2007; 3(Suppl. 2): P-W-101.
27. Chuansumrit A, Husapadol S, Wongwerawattanakoon P, Hongeng S, Sirachainan N, Pakakasama S. Rituximab as an adjuvant therapy to immune tolerance in a haemophilia A boy with high titre inhibitor. Haemophilia 2007; 13: 108-10.
28. Pruthi RK, Schmidt KA, Slaby JA, Hook CC, Nichols WL. Rituximab treatment of FVIII inhibitors in congenital hemophilia A (cHA). J Thromb Haemost 2005; 3(Suppl. 1): Abstract P652.
29. Krause M, Betz C, Scharrer I. Rituximab - a challenge for the therapy of inhibitors to factor VIII. J Thromb Haemost 2003; 1(Suppl. 1): Abstract 1615.
30. Aledort LM, Dimichele DM. Inhibitors occur more frequently in Africo-American and Latino haemophiliacs. Haemophilia 2001; 7: 267-72.
31. Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM, for the RITS-FITNHES Study Group. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-9.